Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. <AVIR.OQ> expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. AVIR.OQ AVIR.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2026
LSEG's mean analyst estimate for Atea Pharmaceuticals, Inc. is for a loss of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Atea Pharmaceuticals, Inc. is $8.00, about 73.5% above its last closing price of $4.61
This summary was machine generated August 3 at 23:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM